Search Results - immunotherapy

133 Results Sort By:
High-Throughput Approach to Identify New Lipid Nanoparticle Formulations for Vaccine and Drug Delivery
High-throughput in vivo screening method to identify lipid nanoparticle (LNP) formulations for local and systemic delivery for mRNA vaccines and cancer immunotherapies. Problem: Nucleic acid delivery is an attractive and rapidly growing area of research, particularly for the development of vaccines and cancer immunotherapy. Historically, viral vectors...
Published: 12/20/2024   |   Inventor(s): Michael Mitchell, Alex Hamilton
Keywords(s): Bioengineering, COVID-19, Drug Delivery, Gene Therapy, Immunology, Immunoncology, Immunotherapy, Infectious Disease, Nanotechnology
Category(s): Technology Classifications > Testing & Measurement, Technology Classifications > Vaccines, Technology Classifications > Therapeutics
T-Cell-Activating Lipid Nanoparticles for Rapid Engineering of CAR T Cells
A method to streamline the process of generating chimeric antigen receptor (CAR) T cells for therapeutic applications. Problem: CAR T cell therapy has demonstrated clinical success in treating various forms of cancer. With more CAR T cell therapies projected to gain regulatory approval, manufacturing becomes increasingly important in the face of this...
Published: 12/20/2024   |   Inventor(s): Ann Metzloff, Margaret Billingsley, Michael Mitchell
Keywords(s): Bioengineering, Cell Therapy, Drug Delivery, Immunoncology, Immunotherapy, Oncology, Platform Technology
Category(s): Technology Classifications > Therapeutics
Method to Alleviate Side Effects of CAR T Cell Immunotherapies
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity). Problem: CAR-T cell therapies lead to many adverse side effects such as cytokine release syndrome (CRS) and neurotoxicity. It has been shown that 20-70% of patients receiving...
Published: 12/20/2024   |   Inventor(s): Michael Mitchell, Ningqiang Gong
Keywords(s): Bioengineering, Cell Therapy, Immunology, Immunoncology, Immunotherapy, Oncology
Category(s): Technology Classifications > Chemical Processes and Synthesis, Technology Classifications > Therapeutics
3D Scaffold for T Cell Delivery and Suppression of Tregs for Solid Tumors (UCLA Case No. 2020-193)
SUMMARY: UCLA researchers in the Department of Bioengineering have developed a small and biodegradable implant that when placed adjacent to solid tumors, enhances immune response to cancer cells. BACKGROUND: The body’s immune system uses proteins called antibodies to train the immune response to foreign pathogens. This mechanism can combat...
Published: 12/3/2024   |   Inventor(s): Manish Butte
Keywords(s): cytokines, Drug Delivery, Immunotherapy, Nanoparticles, scaffolds, solid tumors, T-cell activation, t-cells
Category(s): Platforms > Drug Delivery > Nanoparticles
An Alternative T Cell Redirecting Bispecific Antibody Against Human Cytomegalovirus (UCLA Case No. 2024-198)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have created a novel T cell redirecting bispecific antibody (TRBA) for treatment of cytomegalovirus (CMV) infection. BACKGROUND: The human cytomegalovirus (CMV) has a seroprevalence of about 60% in the USA and nearly 100% of the population in some parts of the world....
Published: 11/15/2024   |   Inventor(s): Otto Yang
Keywords(s): Anti-CD3 antibodies, Bispecific antibodies, CD8 T cells, Human cytomegalovirus (CMV), immunocompromised patients, Immunotherapy, Lymphocytes, T cell redirecting bispecific antibody (TRBA), Transplant, Viral infection
Category(s): Therapeutics > Infectious Diseases, Therapeutics > Immunology And Immunotherapy
Methods To Predict the Efficacy of Neoadjuvant Anti-PD-1 Therapy in Resectable Oral-Cavity Squamous Cell Carcinoma and Target Post-Surgical Relapses (UCLA Case No. 2022-039)
UCLA researchers in the School of Medicine have developed a novel therapeutic strategy to improve prognosis of resectable head and neck cancer patients based on clinical studies. BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is an aggressive and recurrent cancer, ranked sixth among common epithelial malignancies worldwide. Over a third...
Published: 11/4/2024   |   Inventor(s): Roger Lo
Keywords(s): anti-PD-1, head and neck cancer, head and neck squamous cell carcinoma (HNSCC), Immunotherapy, oral cavity squamous cell carcinoma (OCSCC), resectable tumors
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Combination Cancer Therapy Methods and Agents (UCLA Case No. 2024-084)
UCLA researchers from the Department of Medicine, Pathology, & Laboratory Medicine and Molecular & Medical Pharmacology have identified a novel cell-based therapy that leads to enhanced immunotherapy efficacy and overcomes treatment resistance to immune checkpoint blockade in non-small cell lung cancer. BACKGROUND: Non-small cell lung cancer...
Published: 11/4/2024   |   Inventor(s): Bin Liu, Steven Dubinett
Keywords(s): anti-tumor immunity, cell-based therapy, Immune checkpoint blockade, Immunotherapy, non-small cell lung cancer, treatment resistance, Tumor microenvironment, Vaccines
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Respiratory And Pulmonary
Interferon Activation Score Is a Biomarker for Immunotherapy in Malignant Glioma Patients (UCLA Case No. 2024-043)
UCLA researchers from the Department of Neurosurgery have characterized immune responses in malignant glioma patients receiving immunotherapy to develop a robust biomarker that will allow prediction of clinical outcomes following treatment. BACKGROUND: Malignant gliomas are the most common primary brain tumors in adults. No cures exist and most gliomas...
Published: 10/23/2024   |   Inventor(s): Robert Prins
Keywords(s): adjuvant therapy, Biomarker, Chemotherapy, Clinical Trial, dendritic cell vaccination, Glioblastoma, Glioma, immune response, Immunotherapy, interferon, malignant glioma
Category(s): Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Therapeutics > Inflammation And Inflammatory Diseases, Therapeutics > Oncology, Therapeutics > CNS and Neurology
Safe and Potent mRNA Lipid Nanoparticles (LNPs) for Ex-Vivo Engineering of Immunosuppressive T cells in Autoimmunity Therapies.
Using mRNA-LNPs to deliver forkhead box protein 3 (Foxp3) to CD4+ T cells to engineer Foxp3-positive T (FP3T) cells with immunosuppressive properties. Problem: Autoimmune disorders (e.g., type 1 diabetes, multiple sclerosis, and myasthenia gravis) are mediated by self-reactive lymphocyte (B or T cells) expansion. Available suppressive medications like...
Published: 10/1/2024   |   Inventor(s): Michael Mitchell, Ajay Thatte, Alvin Mukalel
Keywords(s): Bioengineering, Cell Therapy, Drug Delivery, Immunology, Immunotherapy, Platform Technology
Category(s): Technology Classifications > Chemical Processes and Synthesis, Technology Classifications > Therapeutics
New Lipiodol Formulation for Treating Hepatocellular Carcinoma with Transarterial Chemoimmunoembolization
NU 2021-148 INVENTORS Dong Hyun Kim* Heegon Kim SHORT DESCRIPTION A new Lipiodol formulation designed to improve the efficacy and safety of transarterial chemoembolization in combination with immunotherapy. BACKGROUND Transarterial chemoembolization...
Published: 11/27/2024   |   Inventor(s):  
Keywords(s): Cancer/Oncology, Drug delivery, Gastrointestinal and Hepatic disease, Immunotherapy, Therapeutics
Category(s): Life Sciences > Therapeutics
1 2 3 4 5 6 7 8 9 10 ...